Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Stage/Subtype:  recurrent adult brain tumor
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 97 for your search:
Start Over
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 22 and over
Trial IDs: EF-19, NCI-2013-00553, NCT01756729
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E3F05, NCI-2011-01971, CDR0000654697, ECOG-E3F05, NCT00978458
A Study of the Efficacy and Safety of Nivolumab Versus Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: SOL-04058-L, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: IRB# 55264, NCI-2012-01118, HCI55264, NCT01580969
Rituximab in Treating Patients with Relapsed or Refractory Lymphoid Malignancies Involving the Central Nervous System
Phase: Phase II, Phase I
Type: Treatment
Age: 3 and over
Trial IDs: 2011-0844, NCI-2012-00849, NCT01596127
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTRC# 12-02, NCI-2014-00900, 1149367, 1-874640-1, 193831, 20141749, HSC20140450X, NCI-2014-00412, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG221-C-003, NCI-2015-01170, NCT02273739
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15702, NCI-2015-02229, H9H-MC-JBEF, NCT02423343
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-209, NCI-2016-00105, NCT02586857
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, CR00018679, CR00021317, CR00022743, CR00023930, eIRB #922, MR00041590, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Bendamustine Hydrochloride in Treating Patients with Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Dacomitinib in Treating Patients with Relapsed or Recurrent Glioblastoma Multiforme
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: 09-468, NCI-2010-02205, NCT01036477, WS573383, NCT01112527
Aminolevulinic Acid in Measuring Brain Tumors in Patients With High Grade Glioma Undergoing Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 to 72
Trial IDs: 10101, NCI-2011-01264, NCT01116661
Proton Beam Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma or Hemangiopericytoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 24309, NCI-2010-01084, NCT01117844
Start Over